Accumulating evidence has demonstrated that RhoGDI2 is expressed differently in different types of human cancer at the mRNA and/or protein levels [12,13,14,15], and it may contribute to aggressive phenotypes by deregulating the Rho GTPase signaling pathway, making it a promising target for cancer therapy [16]. This evidence concerns the gene ARHGDIB and cancer.